Abstract
The scientific development of immunotherapies and radioimmunotherapies of cancer began more than four decades ago. Over time, it has become apparent that the choice of target antigen, immunogenicity of antibodies, length of antibody half-life, ability of antibodies to recruit immune effector functions, decision on conjugation of antibodies to toxins or radionuclides and antibody manufacturing are critical components of successful development of an immunotherapeutic regimen. Anti-idiotype antibodies were some of the first successful monoclonal antibody treatments developed for non-Hodgkins lymphoma. In 1997, the chimeric antibody, Rituximab, was approved by the United States Food and Drug Administration for treatment of patients with relapsed or refractory low-grade or follicular non-Hodgkins lymphoma. In an effort to enhance the efficacy of immunotherapy, toxins and radionuclides have been conjugated to monoclonal antibodies. Ibritumomab, the parent murine antibody of Rituximab, is conjugated to the radioisotope 90Y to create 90Y Ibritumomab tiuxetan, (90Y Zevalin, IDEC-Y2B8). Promising Phase I/II trials have been completed. Phase III experimental trials of 90Y Ibritumomab tiuxetan as treatment for relapsed or refractory NHL are in progress.
Keywords: Non hodgkin, Immunotherapies, Toxins, Radionuclides, Lymphoma, Monoclonal antibodies, CEA, Radioimmunotherapies
Current Pharmaceutical Biotechnology
Title: Antibody-Targeted Immunotherapy for Treatment of Non-Hodgkins Lymphoma
Volume: 1 Issue: 4
Author(s): Christine A. White, Judy R. Berlfein and Antonio J. Grillo-Lopez
Affiliation:
Keywords: Non hodgkin, Immunotherapies, Toxins, Radionuclides, Lymphoma, Monoclonal antibodies, CEA, Radioimmunotherapies
Abstract: The scientific development of immunotherapies and radioimmunotherapies of cancer began more than four decades ago. Over time, it has become apparent that the choice of target antigen, immunogenicity of antibodies, length of antibody half-life, ability of antibodies to recruit immune effector functions, decision on conjugation of antibodies to toxins or radionuclides and antibody manufacturing are critical components of successful development of an immunotherapeutic regimen. Anti-idiotype antibodies were some of the first successful monoclonal antibody treatments developed for non-Hodgkins lymphoma. In 1997, the chimeric antibody, Rituximab, was approved by the United States Food and Drug Administration for treatment of patients with relapsed or refractory low-grade or follicular non-Hodgkins lymphoma. In an effort to enhance the efficacy of immunotherapy, toxins and radionuclides have been conjugated to monoclonal antibodies. Ibritumomab, the parent murine antibody of Rituximab, is conjugated to the radioisotope 90Y to create 90Y Ibritumomab tiuxetan, (90Y Zevalin, IDEC-Y2B8). Promising Phase I/II trials have been completed. Phase III experimental trials of 90Y Ibritumomab tiuxetan as treatment for relapsed or refractory NHL are in progress.
Export Options
About this article
Cite this article as:
White A. Christine, Berlfein R. Judy and Grillo-Lopez J. Antonio, Antibody-Targeted Immunotherapy for Treatment of Non-Hodgkins Lymphoma, Current Pharmaceutical Biotechnology 2000; 1 (4) . https://dx.doi.org/10.2174/1389201003378889
DOI https://dx.doi.org/10.2174/1389201003378889 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hematological Targets of Radiation Damage
Current Drug Targets The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Locked Nucleic Acid Holds Promise in the Treatment of Cancer
Current Pharmaceutical Design Transbronchial Needle Aspiration (TBNA): Past Present and Future
Current Respiratory Medicine Reviews Interferon-α Treatment in Systemic Mastocytosis
Current Drug Targets Quantifying Gp96/Grp94 Complexes Preparations for Vaccines: a Key Step Often Inaccurate
Current Medicinal Chemistry Cytokines in Human Breast Milk: Immunological Significance for Newborns
Current Nutrition & Food Science Genetic Modification of Natural Killer Cells for Leukemia Therapies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry Mitochondria as Possible Pharmaceutical Targets for the Effects of Vitamin E and its Homologues in Oxidative Stress-Related Diseases
Current Pharmaceutical Design Development of <sup>18</sup>F-Labeled PET Probes for Imaging Cell Proliferation
Current Topics in Medicinal Chemistry Defective and Excessive Immunities in Pediatric Diseases
Current Pharmaceutical Design Cancer Stem Cells: Current Status and Therapeutic Implications in Cancer Therapy-A New Paradigm
Current Stem Cell Research & Therapy Clinical Pharmacokinetics of Systemically Administered Antimycotics
Current Clinical Pharmacology Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Catalytic Organic Reactions on ZnO.
Current Organic Synthesis Ectopic Thyroid Gland: Description of a Case and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets The Biphasic Expression Pattern of miR-200a and E-cadherin in Epithelial Ovarian Cancer and its Correlation with Clinicopathological Features
Current Pharmaceutical Design Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety
Current Medicinal Chemistry Studies on Coumarins and Coumarin-Related Compounds to Determine their Therapeutic Role in the Treatment of Cancer
Current Pharmaceutical Design